Easton Pharmaceuticals – EAPH (OTC)
Should you invest in Easton Pharmaceuticals? Recommendation: See below
Easton Pharmaceuticals, Inc. engages in the design, development, and marketing of drugs, therapeutic, and cosmetic healthcare products. It owns wound-healing drug and topically delivered drugs to treat cancer and other therapeutic products. The company was founded by John K. Easton on February 4, 1997 and is headquartered in Toronto, Canada.
Fundamentals
Overview:
HQ: Ontario Canada
Incorporated: in 1997 as LAM Industries. Become Easton Pharms in 2010.
Symbol: OTC: EAPH
Focus:
Easton Pharmaceuticals is more than a pharmaceuticals company. It does own and market drugs to treat cancer and other therapeutic products to treat other conditions. It is also developing a cannabis cultivation business. And it recently bought an interest in a Toronto real estate development project for residential housing. In August 2018, it also signed an LOI to buy a stake in a European casino resort.
Size: (US$)
Stock price: $0.01
Market Cap: $16.3
Enterprise Value: $14.2
Size in the cannabis industry: of 200+
Markets:
Primary: Easton owns and distributes pharma products in several countries. It just bought an operating Greek casino
Secondary: It is developing a cannabis cultivation business and we believe intends to sell wholesale.
Should you invest in Easton Pharmaceuticals? Recommendation: See below
Operations: Weak
Cultivation:
Current production: 0
Future production: Unknown. It has enough ag land to produce over 200,000 kgs year but will need upwards of 2 years to make this happen if it dedicates to this goal.
Canadian market size: In 2017, the total Canadian cannabis market, including the black market, was estimated at roughly 600,000 kgs, or $4.8 billion. Health Canada predicts Canadian cannabis demand in early 2019, after adult-use legalization, could soon reach 1 million kgs/year, and up to $$8-10 billion in revenue in a few years. Current industry inventory is estimated at 300,000 kgs, implying a large shortfall later this year.
Distribution:
It has no cannabis production or distribution yet. It owns distribution rights to several drugs on several continents.
Financials: Weak (no substantial revenue)
Management:
CEO: Evan Karras
Valuation:
Current share price: 0.01
Risks: High
All cannabis companies present risks due to the newness of the industry. This company is extremely risky since it has no revenue yet, and has, by one source, over 1 billion shares outstanding. This is an absurdly high number that puts shareholders in a weak position to make money.
Recommendation: Weak
With no revenue and a huge number of outstanding shares, this is not a company to invest in at the current time.
About Cannin: Cannabis and Hemp Investment Experts
Market analysts expect the cannabis and hemp industry will have an annual value exceeding $75 Billion in the next decade. The time to invest in cannabis and hemp stocks is now! Are you looking to buy stock in hemp companies or cannabis companies? Interested in emerging penny pot stock companies? Looking for the best Canadian pot company to invest in? Cannin is your trusted resource for information about Cannabis and Hemp stock investment opportunities. Our global team of experts evaluates emerging cannabis stock investing companies. We aggregate hundreds of hours of research and distill it down to make it easy for our investors to understand. We provide tips on the best cannabis and hemp stock investments for 2020. We provide the latest hemp investment news and analysis. Visit our site for cannabis investing news and featured companies, sign up for the free Cannin Chronicle or get a free trial of our smart cannabis and hemp stock algorithm to take the guesswork out of profiting from this exciting industry. Predict the price of cannabis and hemp stocks hours in advance with our machine learning algorithm. Is it too late to invest in marijuana? No! This is the perfect time.
Profit from the best Cannabis and Hemp stocks – we’ll show you how at cannin.com